We evaluated the prediction of subsequent adverse events in a new 4-group LVH classification based on LV dilatation ( high LV end-diastolic volume [ EDV ] index ) and concentricity ( mass/end-diastolic volume [ M/EDV ] ( 2/3 ) ) in hypertensive patients .